Study Title and Description
Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60.|
|Author||Cohen FJ., Watts S., Shah A., Akers R., Plouffe L.|
|Country||Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana 46285, USA.|
Pubmed ID: 10636511
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.